Innovative medical care: If the stock price deviates by more than 20% for three consecutive days, it indicates trading risks.

The innovative medical announcement stated that the company's stock had a cumulative deviation from the closing price on January 8th, 9th, and 12th, 2026, exceeding 20%, which was considered abnormal fluctuation. After verification, there were no corrections or supplements to the information previously disclosed by the company, and there were no major undisclosed events related to production, operation, or internal and external environment changes. The controlling shareholder and the actual controller did not buy or sell the company's stock. The company noted that the market had a high level of interest in the brain-computer interface business, and its subsidiary, Boling Brain-Computer Products CyberLing Science AC5, was listed in October 2025, generating revenue of 114,000 yuan in 2025. CyberLing Science AM5 did not generate any revenue, and Boling Brain-Computer had operating losses in 2023-2024. The company reminded investors to make rational investments.